These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33648458)

  • 1. Blinatumomab-induced T cell activation at single cell transcriptome resolution.
    Huo Y; Sheng Z; Lu DR; Ellwanger DC; Li CM; Homann O; Wang S; Yin H; Ren R
    BMC Genomics; 2021 Mar; 22(1):145. PubMed ID: 33648458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
    Meckler JF; Levis DJ; Vang DP; Tuscano JM
    Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.
    Wong R; Pepper C; Brennan P; Nagorsen D; Man S; Fegan C
    Haematologica; 2013 Dec; 98(12):1930-8. PubMed ID: 23812940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E
    Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
    Kobayashi T; Ubukawa K; Fujishima M; Takahashi N
    Int J Hematol; 2021 Apr; 113(4):600-605. PubMed ID: 33387296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Ocadlikova D; Lussana F; Fracchiolla N; Bonifacio M; Santoro L; Delia M; Chiaretti S; Pasciolla C; Cignetti A; Forghieri F; Grimaldi F; Corradi G; Zannoni L; De Propris S; Borleri GM; Tanasi I; Vadakekolathu J; Rutella S; Guarini AR; Foà R; Curti A;
    Br J Haematol; 2023 Nov; 203(4):637-650. PubMed ID: 37700538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
    Duminuco A; Markovic U; Parrinello NL; Lo Nigro L; Mauro E; Vetro C; Parisi M; Maugeri C; Fiumara PF; Milone G; Romano A; Di Raimondo F; Leotta S
    Front Immunol; 2023; 14():1195734. PubMed ID: 37809082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytofluorimetric assay to investigate variability in blinatumomab
    Braidotti S; Franca R; Granzotto M; Piscianz E; Tommasini A; Rabusin M; Stocco G; Decorti G
    Front Biosci (Landmark Ed); 2022 Jan; 27(2):39. PubMed ID: 35226982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab's antitumor activity against B-cell malignancy.
    Chen YH; Wang Y; Liao CH; Hsu SC
    Sci Rep; 2021 Jun; 11(1):12398. PubMed ID: 34117317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
    Halford Z; Coalter C; Gresham V; Brown T
    Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.